Menu
Search
|

Menu

Close
X

Eloxx Pharmaceuticals Inc ELOX.OQ (NASDAQ Stock Exchange Global Market)

15.64 USD
-0.55 (-3.40%)
As of May 18
chart
Previous Close 16.19
Open 16.35
Volume 9,671
3m Avg Volume --
Today’s High 16.35
Today’s Low 15.64
52 Week High 16.35
52 Week Low 10.30
Shares Outstanding (mil) 32.66
Market Capitalization (mil) 528.73
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.624
FY17
-8.674
FY16
-8.278
FY15
-26.935
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.53
Price to Sales (TTM)
vs sector
--
8.85
Price to Book (MRQ)
vs sector
31.88
4.22
Price to Cash Flow (TTM)
vs sector
--
21.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.69
LT Debt to Equity (MRQ)
vs sector
0.00
12.76
Return on Investment (TTM)
vs sector
-303.35
12.63
Return on Equity (TTM)
vs sector
-374.65
14.50

EXECUTIVE LEADERSHIP

Robert Ward
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Gregory Weaver
Chief Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Pedro Huertas
Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Zafrira Avnur
Director, Since 2017
Salary: --
Bonus: --
Tomer Kariv
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

950 Winter St
WALTHAM   MA   02451-1424

Phone: +1858.9090749

Eloxx Pharmaceuticals, Inc., formerly Sevion Therapeutics, Inc., is a biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The Company’s lead product candidate is ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. The ELX-02, which is in Phase I clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. As part of clinical program, the Company has completed a Phase Ia single ascending dose study in Israel and Belgium. The Company also intends to advance one or more additional molecules from its drug product candidate library toward clinical development.

SPONSORED STORIES